°Ç¸ç³Ô¹Ï

To subscribe to monthly email alerts of MHRA Safety Roundup visit our Ìý

Download Document

Please access the PDF version of our Safety Roundup for our easy-read template and QR codes to access the full articles.

Letters, medicines recalls and device notifications sent to healthcare professionals inÌýMarch 2026Ìý

Direct Healthcare Professional CommunicationsÌý

We received notification that the following Direct Healthcare Professional Communications were sent or provided to relevant healthcare professionals in March 2026:

• Ìý

• Ìý

• ÌýÌý

Medicine Recalls and Notifications

InÌýMarch 2026,Ìýrecalls and notifications for medicines were issued on:

Class 2 Medicines Recall: Bio Products Laboratory Limited, Rabies, Human normal Immunoglobulin 500IU solution for Injection, EL(26)A/18. Issued 30 March 2026.

Bio Products Laboratory Limited is recalling one batch of Human Rabies Immunoglobulin following a stability failure for this batch. The batch has shown a reduction in potency of the Human Rabies immunoglobulin.

Class 2 Medicines Recall:ÌýRegent Medical Limited /ÌýMölnlyckeÌýHealth Care,ÌýHibiwashÌý500ml,ÌýEL(26)A/15. Issued 23 March 2026.Ìý

Mölnlycke Health Care are recalling specific batches ofÌýHibiwashÌýdue to microbial contamination at the manufacturing facility, following routine weekly microbiological monitoring.ÌýÌý

Class 2 Medicines Recall:ÌýCrescent Pharma Limited, Ramipril 5mg capsules,ÌýEL(26)A/11.ÌýIssuedÌý6 March 2026.Ìý

Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure due to a potential error at the manufacturing site. Following a complaint, it was identified that a pack of Ramipril 5 mg Capsules contained blister strips of Amlodipine 5 mg Tablets inside the sealed carton.Ìý

Class 2 Medicines Recall:ÌýRokshawÌýLimited Trading asÌýCuraleafÌýLaboratories,ÌýCuraleafÌýOil [FS] 10mg/ml THC, 10mg/ml CBD (30ml),ÌýEL(26)A/13.ÌýIssuedÌý12 March 2026.Ìý

CuraleafÌýLaboratories are recalling three batches ofÌýCuraleafÌýOil [FS] 10mg/ml THC 10mg/ml CBD (30ml) due to low THC content.Ìý

Class 3 Medicines Recall:ÌýBayer Plc,ÌýGastrografinÌýgastroenteralÌýsolution,ÌýUrografinÌý150 Infusion andÌýUrografinÌý150 Injection,ÌýEL(26)A/12.ÌýIssued 12 MarchÌý2026.ÌýÌý

Bayer Plc is recalling all stock of the products listed in this notification as a precautionary measure due to the identification of an impurity above the acceptable limit. The recall is at pharmacy and wholesaler level.ÌýÌý

Class 4 Medicines Defect Notification:ÌýBaxter Healthcare Corporation,ÌýOnkotroneÌýInjection 2 mg/ml concentrate for solution for infusion,ÌýEL(26)A/14.ÌýIssued 17 MarchÌý2026.Ìý

Baxter Healthcare Corporation have informed the MHRA that the Patient Information Leaflet (PIL) packed in specified batches does notÌýcontainÌýup to date information relating to the duration of contraceptionÌýrequiredÌýfor females after stopping taking this medication.Ìý

Class 4 Medicines Defect Notification:ÌýQuadrant Pharmaceuticals Limited,ÌýVesomniÌý6 mg/0.4 mg modified release tablets,ÌýEL(26)A/16.ÌýIssued 26 March 2026.Ìý

Quadrant Pharmaceuticals Limited have informed the MHRA that their parallel imported packs ofÌýVesomniÌý6 mg/0.4 mg modified release tablets have been printed with the incorrect barcode/GTIN on the carton.

Class 4 Medicines Defect Notification: Sandoz Limited, Apixaban 2.5mg and 5mg Tablets, EL(26)A/17. Issued 26 March 2026.

Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information.

ÌýMedical Device Field Safety NoticesÌý

Find recently published Field SafetyÌýNoticesÌý

Report suspected drug reactions and device incidents on a Yellow Card

Please continue to report suspected adverse drug reactions and device incidents. Your report will help us safeguard public health.Ìý

When reporting, please provide as much information as possible, including information about medical history, any concomitant medication, onset timing, treatment dates and particularly if a side effect continued or started after treatment was stopped.Ìý

Report a medicine

Healthcare professionals should report via a Yellow Card to:Ìý

• ³Ù³ó±ð 
• theÌýYellow Card app; download from ³Ù³ó±ð  o°ù 
• someÌýclinical IT systems for healthcare professionals (EMIS,ÌýSystmOne, Vision,ÌýMiDatabank, and Ulysses)Ìý

Reporting for medical devicesÌý

Healthcare professionals should report incidents:Ìý

• inÌýEngland and Wales to the or via the Yellow Card app
• inÌýScotland to and their local incident recording system
• inÌýNorthern Ireland to theÌýYellow Card websiteÌýin accordance withÌýyour organisation’s medical device policies and procedures

Reporting for patientsÌý

Patients should report via a Yellow Card to:Ìý

• theÌýÌý
• theÌýYellow Card app; download from ³Ù³ó±ð  o°ù Ìý

News Roundup

Publication of meningitis factsheet

The MHRA has published a new meningitis patient factsheet, designed to provide information and guidance on what meningitis is, the different types of infection, how it spreads, and the symptoms that may require urgent medical attention.

The factsheet covers the differences between bacterial and viral meningitis and who may be most vulnerable to severe disease. It also summarises the vaccines used in the UK to protect against meningitis-causing bacteria, and the evidence supporting their safety and effectiveness.

This resource is now available for healthcare professionals, patients and the public. For more information, view the full Meningitis – Patient Factsheet.

Patients to get new medicines up to six months sooner under new joint MHRA-NICE approval process

The MHRA and NICE aligned pathway and an improved advice service will help get new medicines to patients faster and support companies to plan with more certainty.
Patients in England are set to receive some new medicines three to six months earlier under a streamlined approval process being launched by the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE).

This follows commitments in the government’s 10 Year Health Plan for England and Life Sciences Sector Plan for NICE and the MHRA to work together more closely to get medicines to patients sooner. The aligned pathway, which launches on 1 April, will help to bring NICE’s decision-making process forward to run alongside MHRA’s, resulting in decisions on licencing and value being made at the same time. Read the full article for more information.

To subscribe to monthly email alerts of MHRA Safety Roundup visitÌýourÌýÌý

For any enquiries, please contactÌýinfo@mhra.gov.uk